Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer
NL-OMON59754Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of PF-08634404 in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Pfizer. Primary endpoints: Progression-free survival by BICR and Overall survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
PF-08634404
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON59754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59754.